^
    Apply
    Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (NCT05881265)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/15/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    RARA • PML
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (NCT02390752)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    04/29/2015
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NF1
    |
    Turalio (pexidartinib)
    Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia (NCT01409161)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    10/05/2011
    Primary completion :
    12/18/2025
    Completion :
    12/18/2025
    RARA • PML
    |
    Mylotarg (gemtuzumab ozogamicin) • Vesanoid (tretinoin) • arsenic trioxide
    Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia (ECOG-ACRIN-EA9131) (NCT03253848)
    Phase N/A
    ECOG-ACRIN Cancer Research Group
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    09/26/2017
    Primary completion :
    06/30/2024
    Completion :
    08/18/2025
    RARA
    Optimum Induction Therapy of Low-risk APL (NCT05832320)
    Phase N/A
    Peking University People's Hospital
    Recruiting
    Last update posted :
    05/10/2024
    Initiation :
    01/01/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    RARA • PML
    |
    etoposide IV • daunorubicin
    Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia (NCT04793919)
    Phase 2
    Associazione Italiana Ematologia Oncologia Pedi...
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    10/09/2019
    Primary completion :
    10/09/2025
    Completion :
    10/10/2027
    RARA • PML
    |
    Mylotarg (gemtuzumab ozogamicin) • arsenic trioxide
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    RWE of 1st Line Treatment With ATO/ATRA for Adult APL (NCT04897490)
    Phase N/A
    Grupo Argentino de Tratamiento de la Leucemia A...
    Recruiting
    Last update posted :
    01/09/2024
    Initiation :
    03/01/2021
    Primary completion :
    07/01/2026
    Completion :
    12/01/2026
    BCR
    |
    FLT3 mutation
    |
    Vesanoid (tretinoin) • arsenic trioxide
    Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia (NCT02339740)
    Phase 3
    Children's Oncology Group
    Active, not recruiting
    Last update posted :
    11/22/2023
    Initiation :
    07/21/2015
    Primary completion :
    10/31/2020
    Completion :
    09/22/2024
    FLT3 • RARA • PML
    |
    FLT3 mutation • FLT3 wild-type
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • Vesanoid (tretinoin) • arsenic trioxide • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064) (NCT02688140)
    Phase 3
    Technische Universität Dresden
    Active, not recruiting
    Last update posted :
    11/02/2023
    Initiation :
    06/01/2016
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    cytarabine • idarubicin hydrochloride • mitoxantrone • arsenic trioxide • mercaptopurine
    Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML (DaunoDouble) (NCT02140242)
    Phase 3
    Technische Universität Dresden
    Completed
    Last update posted :
    09/15/2023
    Initiation :
    04/16/2014
    Primary completion :
    04/25/2022
    Completion :
    04/25/2022
    NPPB
    |
    daunorubicin
    Diagnostic Study of Patients With Acute Lymphoblastic Leukemia or Acute Promyelocytic Leukemia (NCT00003861)
    Phase N/A
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    08/31/2023
    Initiation :
    04/01/1999
    Primary completion :
    01/01/2100
    ABL1 • BCR
    A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia (NCT01756118)
    Phase 1
    Goethe University
    Completed
    Last update posted :
    02/16/2023
    Initiation :
    06/01/2012
    Primary completion :
    12/01/2017
    Completion :
    02/07/2020
    ABL1 • BCR
    |
    dactolisib (RTB101) • sirolimus
    S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia (NCT00492856)
    Phase 3
    Southwest Oncology Group
    Completed
    Last update posted :
    01/10/2023
    Initiation :
    06/01/2007
    Primary completion :
    12/01/2013
    Completion :
    05/04/2016
    PML
    |
    Chr t(15;17)
    |
    methotrexate • Mylotarg (gemtuzumab ozogamicin) • mercaptopurine
    Phase III Trial in Acute Promyelocytic Leukemia Patients (APL0406) (NCT00482833)
    Phase 3
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Completed
    Last update posted :
    10/11/2022
    Initiation :
    08/01/2007
    Primary completion :
    09/01/2012
    Completion :
    10/17/2019
    PML
    |
    PML-RARA fusion • Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
    |
    idarubicin hydrochloride • arsenic trioxide • mercaptopurine
    Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia (NCT01253070)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/04/2022
    Initiation :
    04/01/2011
    Primary completion :
    10/31/2014
    Completion :
    04/15/2021
    FLT3 • RUNX1
    |
    FLT3 mutation • Chr t(15;17)
    |
    sorafenib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
    A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia (NCT02200978)
    Phase 4
    South China Children's Leukemia Group
    Completed
    Last update posted :
    05/10/2022
    Initiation :
    09/01/2011
    Primary completion :
    10/01/2021
    Completion :
    10/01/2021
    PML
    |
    RARA positive
    |
    cytarabine • methotrexate • mitoxantrone • arsenic trioxide • mercaptopurine
    Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy (NCT01404949)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    11/30/2021
    Initiation :
    07/01/2011
    Primary completion :
    02/01/2021
    Completion :
    02/01/2021
    TERT • PML
    |
    arsenic trioxide
    Acute Myeloid Leukemia T Cell Depletion to Improve Transplants in Adults With Acute Myeloid Leukemia (BMT CTN 0303) (NCT00201240)
    Phase 2
    National Heart, Lung, and Blood Institute (NHLBI)
    Completed
    Last update posted :
    11/01/2021
    Initiation :
    06/01/2005
    Primary completion :
    12/01/2013
    Completion :
    12/01/2013
    HLA-DRB1 • CD34 • HLA-B • HLA-C
    Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL) (NCT01191541)
    Phase 4
    Xiaofan Zhu
    Completed
    Last update posted :
    08/10/2021
    Initiation :
    05/01/2010
    Primary completion :
    02/01/2017
    Completion :
    02/01/2017
    RARA
    |
    cytarabine • daunorubicin • arsenic trioxide
    Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia (NCT01445080)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/02/2021
    Initiation :
    05/30/2006
    Primary completion :
    03/16/2012
    Completion :
    12/10/2012
    FLT3
    |
    FLT3-ITD mutation
    |
    sorafenib
    Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001)
    Phase 2
    Fred Hutchinson Cancer Center
    Completed
    Last update posted :
    10/30/2019
    Initiation :
    11/01/2004
    Primary completion :
    05/01/2011
    Completion :
    05/08/2015
    HLA-DRB1 • HLA-B
    |
    sirolimus • fludarabine IV
    Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL (APL2012) (NCT01987297)
    Phase 4
    Shanghai Jiao Tong University School of Medicine
    Unknown status
    Last update posted :
    08/19/2019
    Initiation :
    06/01/2012
    Primary completion :
    12/31/2020
    Completion :
    12/31/2020
    RARA • PML
    |
    cytarabine • daunorubicin • idarubicin hydrochloride • arsenic trioxide
    All-trans Retinoic Acid, and Arsenic +/- Idarubicin (NCT00413166)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/07/2019
    Initiation :
    12/01/2006
    Primary completion :
    02/01/2016
    Completion :
    02/01/2016
    RARA • PML
    |
    Mylotarg (gemtuzumab ozogamicin) • idarubicin hydrochloride • arsenic trioxide
    Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy (NCT01051063)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    11/29/2018
    Initiation :
    12/09/2009
    Primary completion :
    04/26/2016
    Completion :
    04/26/2016
    WT1
    |
    GSK2130579A
    Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML) (NCT00725283)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    08/07/2018
    Initiation :
    10/01/2008
    Primary completion :
    06/22/2016
    Completion :
    06/22/2016
    WT1
    |
    GSK2130579A
    Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia (NCT01548911)
    Phase 2
    Wake Forest University Health Sciences
    Withdrawn
    Last update posted :
    07/02/2018
    Initiation :
    05/01/2012
    Primary completion :
    09/01/2013
    Completion :
    09/01/2013
    CD33
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin)
    Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia (NCT02991066)
    Phase N/A
    First Affiliated Hospital of Harbin Medical Uni...
    Unknown status
    Last update posted :
    04/24/2018
    Initiation :
    10/01/2014
    Primary completion :
    12/01/2019
    Completion :
    12/01/2020
    RARA
    A Safety Study of SGN-CD33A in AML Patients (NCT01902329)
    Phase 1
    Seagen Inc.
    Completed
    Last update posted :
    01/05/2018
    Initiation :
    07/01/2013
    Primary completion :
    03/18/2016
    Completion :
    12/08/2017
    CD33
    |
    CD33 positive
    |
    azacitidine • vadastuximab talirine (SGN-CD33A)
    Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia (NCT01226303)
    Phase 3
    Associazione Italiana Ematologia Oncologia Pedi...
    Unknown status
    Last update posted :
    01/26/2017
    Initiation :
    01/01/2009
    Primary completion :
    06/01/2017
    Completion :
    12/01/2018
    NPM1 • RARA • PML
    French Registry of First-line Treatment of Acute Promyelocytic Leukemia (NCT02938858)
    Phase N/A
    Groupe Francophone des Myelodysplasies
    Recruiting
    Last update posted :
    10/19/2016
    Initiation :
    10/01/2015
    Primary completion :
    10/01/2020
    Completion :
    10/01/2022
    RARA
    Infection and Tumour Antigen Cellular Therapy (INTACT-WT1) (NCT02895412)
    Phase 1
    University of Sydney
    Unknown status
    Last update posted :
    09/09/2016
    Initiation :
    08/01/2016
    Primary completion :
    12/01/2020
    Completion :
    12/01/2020
    WT1
    |
    WT1 overexpression
    New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia (NCT00670150)
    Phase 2
    University of Southern California
    Withdrawn
    Last update posted :
    10/27/2015
    Initiation :
    05/01/2010
    Primary completion :
    08/01/2010
    Completion :
    08/01/2010
    RARA
    |
    arsenic trioxide
    Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia (NCT00588809)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    08/05/2015
    Initiation :
    12/01/2007
    Primary completion :
    04/01/2012
    Completion :
    12/01/2012
    RAS
    |
    RAS mutation
    |
    Koselugo (selumetinib)
    Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia (NCT01146223)
    Phase N/A
    Children's Oncology Group
    Completed
    Last update posted :
    05/07/2015
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2011
    Completion :
    06/01/2011
    VEGFA • WT1